Evidence map›Paper›PMID 39820410›Full record

ArticleChinese medical journal2025

Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study.

Yuankai Shi, Qingyuan Zhang, Junsheng Wang, Zhong Ouyang, Tienan Yi, Jiazhuan Mei, Xinshuai Wang, Zhidong Pei, Tao Sun, Junheng Bai and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yuankai ShiDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Qingyuan ZhangDepartment of Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, China.
Junsheng WangDepartment of Oncology, Anyang Cancer Hospital, Anyang, Henan 455000, China.
Zhong OuyangDepartment of Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000, China.
Tienan YiDepartment of Oncology, Xiangyang Central Hospital, Xiangyang, Hubei 441000, China.
Jiazhuan MeiDepartment of Oncology, Zhengzhou People's Hospital, Zhengzhou, Henan 450000, China.
Xinshuai WangDepartment of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471000, China.
Zhidong PeiDepartment of Oncology, Luoyang Central Hospital, Luoyang, Henan 471000, China.
Tao SunDepartment of Oncology, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital, Shenyang, Liaoning 110000, China.
Junheng BaiDepartment of Breast, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi 046000, China.
Shundong CangDepartment of Oncology, Henan Provincial People's Hospital, Zhengzhou, Henan 450000, China.
Yarong LiDepartment of Oncology & Hematology, The Second Hospital of Jilin University, Changchun, Jilin 130000, China.
Guohong FuDepartment of General Surgery, Sanya Central Hospital (Hainan Third People's Hospital), Sanya, Hainan 572000, China.
Tianjiang MaDepartment of Oncology, Luohe Central Hospital, Luohe, Henan 462000, China.
Huaqiu ShiDepartment of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, China.
Jinping LiuDepartment of Galactophore Surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610000, China.
Xiaojia WangDepartment of Breast Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310000, China.
Hongrui NiuDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medial University, Xinxiang, Henan 453000, China.
Yanzhen GuoDepartment of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471000, China.
Shengyu ZhouDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Li SunXiamen Amoytop Biotech Co., LTD, Xiamen, Fujian 361000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39820410
PMCPMC11845196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.